Intensity Therapeutics (NASDAQ:INTS) Issues Earnings Results

Intensity Therapeutics (NASDAQ:INTS) announced its quarterly earnings data on Thursday. The company reported ($1.09) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.99) by ($0.10), FiscalAI reports.

Here are the key takeaways from Intensity Therapeutics’ conference call:

• Intensity ended the quarter with $8.5 million in cash and expects operating cash burn of about $1 million per month in Q4; it may continue raising capital through its ATM and other financing. Funding is gating the pace of enrollment and site activations, particularly for INVINCIBLE-3.
• In INVINCIBLE-4, preliminary results showed a pathological complete response in 71% of patients receiving INT230-6 plus standard care, versus 42% with standard care alone; all seven INT230-6 patients had tumor necrosis. Management emphasized the sample is very small, and an independent safety review is assessing whether the revised dosing regimen resolved prior localized skin issues.
• INVINCIBLE-3 enrollment has restarted at a limited number of U.S. sites, but no patients had yet been randomized; management expects to begin with roughly 10 enrolling sites, with expansion dependent on funding. The study will use central CT review and Choi density-based criteria to assess progression, while overall survival remains the endpoint.
• Management said business-development discussions with multinational and regional companies are ongoing, with interest in either or both clinical programs, but described the talks as early-stage. Potential arrangements could include licensing or partner funding, but no agreement was announced.

Intensity Therapeutics Price Performance

Shares of NASDAQ:INTS traded down $0.10 during mid-day trading on Friday, reaching $3.00. The stock had a trading volume of 15,416 shares, compared to its average volume of 20,049. The company has a current ratio of 5.00, a quick ratio of 5.00 and a debt-to-equity ratio of 0.01. The company has a market cap of $9.78 million, a P/E ratio of -0.84 and a beta of 2.78. Intensity Therapeutics has a 1 year low of $2.80 and a 1 year high of $15.00. The business’s 50 day moving average price is $3.63 and its 200 day moving average price is $5.10.

Wall Street Analyst Weigh In

Several research firms have recently commented on INTS. Weiss Ratings reissued a “sell (e+)” rating on shares of Intensity Therapeutics in a report on Monday, October 19th. HC Wainwright raised their target price on shares of Intensity Therapeutics from $5.00 to $7.00 and gave the company a “buy” rating in a research note on Tuesday, August 18th. Finally, Citigroup reaffirmed a “buy” rating on shares of Intensity Therapeutics in a research note on Tuesday, August 11th. One research analyst has rated the stock with a Strong Buy rating, three have given a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $7.00.

About Intensity Therapeutics

Intensity Therapeutics, Inc (NASDAQ: INTS) is a clinical-stage biotechnology company developing investigational cancer immunotherapies designed to treat solid tumors. Its approach focuses on injecting therapies directly into tumors to promote tumor-cell destruction and stimulate a broader immune response against cancer.

The company’s lead product candidate, INT230-6, is a proprietary formulation containing the chemotherapy agents cisplatin and vinblastine combined with an amphiphilic delivery agent.